Steven Cohen Syndax Pharmaceuticals Inc Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,255,047 shares of SNDX stock, worth $70.7 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

4,255,047

Previous 2,127,467 100.01%

Holding current value

$70.7 Million

Previous $19.9 Million 228.51%

% of portfolio

0.13%

Previous 0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$8.73 - $17.04 $18.6 Million - $36.3 Million	2,127,580 Added 100.01%	4,255,047 $65.5 Million
Q2 2025 Aug 14, 2025	SELL	$8.9 - $14.15 $16.7 Million - $26.6 Million	-1,881,233 Reduced 46.93%	2,127,467 $19.9 Million
Q1 2025 May 15, 2025	BUY	$12.29 - $16.38 $25.7 Million - $34.3 Million	2,092,964 Added 109.25%	4,008,700 $49.3 Million
Q4 2024 Feb 14, 2025	SELL	$12.52 - $21.81 $10.8 Million - $18.8 Million	-862,531 Reduced 31.05%	1,915,736 $25.3 Million
Q3 2024 Nov 14, 2024	SELL	$17.93 - $24.81 $82,226 - $113,778	-4,586 Reduced 0.16%	2,778,267 $53.5 Million
Q2 2024 Aug 14, 2024	BUY	$18.82 - $23.79 $13.5 Million - $17 Million	716,168 Added 34.65%	2,782,853 $57.1 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $15.1 Million - $18.9 Million	-767,814 Reduced 27.09%	2,066,685 $49.2 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $8.43 Million - $16 Million	740,298 Added 35.35%	2,834,499 $61.3 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $12.5 Million - $18.7 Million	859,401 Added 69.6%	2,094,201 $30.4 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $13.7 Million - $15.8 Million	710,400 Added 135.47%	1,234,800 $25.8 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $8.24 Million - $11.6 Million	-399,000 Reduced 43.21%	524,400 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $19.1 Million - $24.2 Million	923,400 New	923,400 $23.5 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $4.91 Million - $7.01 Million	-360,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $102,396 - $152,835	6,900 Added 1.95%	360,000 $6.26 Million
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $1.64 Million - $2.42 Million	-107,800 Reduced 23.39%	353,100 $7.73 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $2.06 Million - $2.94 Million	148,500 Added 47.54%	460,900 $8.81 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $8.51 Million - $16 Million	-634,400 Reduced 67.0%	312,400 $5.36 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $3.8 Million - $4.85 Million	-197,100 Reduced 17.23%	946,800 $21.2 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $14.8 Million - $25.9 Million	977,863 Added 588.94%	1,143,900 $25.4 Million
Q3 2020 Nov 16, 2020	BUY	$13.39 - $17.48 $2.22 Million - $2.9 Million	166,037 New	166,037 $2.45 Million
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $612,000 - $1.43 Million	-170,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $1.08 Million - $1.37 Million	170,000 New	170,000 $1.37 Million
Q2 2018 Aug 14, 2018	SELL	$6.93 - $14.63 $2.08 Million - $4.39 Million	-300,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $2.61 Million - $4.45 Million	300,000 New	300,000 $4.27 Million

Others Institutions Holding SNDX

# of Institutions

255

Shares Held

99.9M

Call Options Held

1.41M

Put Options Held

737K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $940M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account